Saira Khalique

Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors

Timothy A. Yap, Brent O’Carrigan, Marina S. Penney et al. · Journal of Clinical Oncology · 2020 · 248 citations · Full text

Medicine, Oncology, Pharmacology +17

Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study

David J. Pinato, Daniela Ferrante, Georgina Hanbury et al. · The Lancet Oncology · 2022 · 80 citations · Full text

Medicine, Infectious Diseases, Oncology +16

Optimised ARID1A immunohistochemistry is an accurate predictor of <i>ARID1A</i> mutational status in gynaecological cancers

Saira Khalique, Kalnisha Naidoo, Ayoma D. Attygalle et al. · The Journal of Pathology Clinical Research · 2018 · 78 citations · Full text

Medicine, Oncology, Pathology +17

ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI)

Susana Banerjee, James Stewart, Núria Porta et al. · International Journal of Gynecological Cancer · 2021 · 69 citations · Full text

Medicine, Oncology, Pharmacology +17

First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial

Christian Marth, Richard G. Moore, Mariusz Bidziński et al. · Journal of Clinical Oncology · 2024 · 58 citations · Full text

Medicine, Oncology, Pharmacotherapy +13